epirubicin has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balatoni, T; Biró, K; Danyi, T; Géczi, L; Küronya, Z; Liszkay, G; Tóth, E | 1 |
1 other study(ies) available for epirubicin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
Topics: Aged; Antibodies, Monoclonal; Carcinoma, Basal Cell; Carcinoma, Transitional Cell; COVID-19; Epirubicin; Female; Humans; Immune Checkpoint Inhibitors; Skin Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |